Michael Reedijk, University of Toronto

Research

Immunotherapy Notch Signaling Caspase 1 Cytotoxic T Lymphocyte Il1 Beta Immune Checkpoint Blockade Randomized Control Trial Triple-Negative Breasat Cancer

Latest papers

A handheld device for intra-cavity and ex vivo fluorescence imaging of breast conserving surgery margins with 5-aminolevulinic acid.
BMC biomedical engineering · 2024
Inhibition of Notch enhances efficacy of immune checkpoint blockade in triple-negative breast cancer.
Science advances · 2024 · senior author
Evaluating persistent T1-weighted lesions without concurrent abnormal enhancement on breast MRI in neoadjuvant chemotherapy patients: implications for complete pathological response.
European radiology · 2024

All 32 publications

Latest funding

Rebooting Sensitivity to Checkpoint Blockade Therapy in TNBC (RESETT)
CIHR · 2026 · Nominated PI
$872,100
Cell Signaling Pathways in Triple Negative Breast Cancer: Effects on Stemness Cell, Cell Survival, and The Tumor Micorenvironment
CIHR · 2022 · Supervisor
$6,000
The role of Hedgehog signaling in basal-like breast cancer and the tumour microenvironment
CIHR · 2019 · Supervisor
$105,000

All 6 grants and awards

32 publications.

01

A handheld device for intra-cavity and ex vivo fluorescence imaging of breast conserving surgery margins with 5-aminolevulinic acid.

Gibson C, Wang SC, Phoon A, Thalanki Anantha N, Ottolino-Perry K, Petropoulos S, Qureshi Z, Subramanian V, Shahid A, O'Brien C, Carcone S, Chung S, Tsui T, Son V, Sukhram M, Meng F, Done SJ, Easson AM, Cil T, Reedijk M, Leong WL, DaCosta RS

BMC biomedical engineering2024

DOI: 10.1186/s42490-024-00079-9 PMID: 38822389

02

Inhibition of Notch enhances efficacy of immune checkpoint blockade in triple-negative breast cancer.

Shen Q, Murakami K, Sotov V, Butler M, Ohashi PS, Reedijk M

Science advances2024Senior author

DOI: 10.1126/sciadv.ado8275 PMID: 39475614

03

Evaluating persistent T1-weighted lesions without concurrent abnormal enhancement on breast MRI in neoadjuvant chemotherapy patients: implications for complete pathological response.

Goulam-Houssein S, Ye XY, Fleming R, Au F, Kulkarni S, Ghai S, Amitai Y, Reedijk M, Freitas V

European radiology2024

DOI: 10.1007/s00330-024-10695-7 PMID: 38491128

04

Caspase-1-dependent spatiality in triple-negative breast cancer and response to immunotherapy.

Zheng W, Marini W, Murakami K, Sotov V, Butler M, Gorrini C, Ohashi PS, Reedijk M

Nature communications2024Senior author

DOI: 10.1038/s41467-024-52553-6 PMID: 39353903

05

Exploring immune interactions in triple negative breast cancer: IL-1β inhibition and its therapeutic potential.

Wilson BE, Shen Q, Cescon DW, Reedijk M

Frontiers in genetics2023Senior author

DOI: 10.3389/fgene.2023.1086163 PMID: 37065483

06

Targeting Notch-Driven Cytokine Secretion: Novel Therapies for Triple Negative Breast Cancer.

Marini W, Wilson BE, Reedijk M

DNA and cell biology2023Senior author

DOI: 10.1089/dna.2022.0578 PMID: 36579947

07

2023 Canadian Surgery Forum

Brière R, Habashi R, Merchant S, Cadili L, Alhumoud Z, Lau R, Gawad N, Valji R, Balmes PN, Tan JGK

Canadian Journal of Surgery20231 citationsOpen Access

DOI: 10.1503/cjs.014223 PMID: W4389488805

08

Therapeutic inhibition of USP9x-mediated Notch signaling in triple-negative breast cancer.

Jaiswal A, Murakami K, Elia A, Shibahara Y, Done SJ, Wood SA, Donato NJ, Ohashi PS, Reedijk M

Proceedings of the National Academy of Sciences of the United States of America2021Senior author

DOI: 10.1073/pnas.2101592118 PMID: 34518219

09

Lack of definitive presurgical pathological diagnosis is associated with inadequate surgical margins in breast-conserving surgery.

Nasute Fauerbach PV, Tyryshkin K, Rodrigo SP, Rudan J, Fichtinger G, Reedijk M, Varma S, Berman DM

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology2021

DOI: 10.1016/j.ejso.2021.05.047 PMID: 34120811

10

Notch Signaling and the Breast Cancer Microenvironment.

Shen Q, Reedijk M

Advances in experimental medicine and biology2021Senior author

DOI: 10.1007/978-3-030-55031-8_12 PMID: 33034033

Rebooting Sensitivity to Checkpoint Blockade Therapy in TNBC (RESETT)

Nominated PICIHR2026Project Grant

Principal investigators: Reedijk, Michael

Keywords: Caspase 1; Cytotoxic T Lymphocyte; Il1 Beta; Immune Checkpoint Blockade; Immunotherapy; Notch Signaling; Randomized Control Trial; Triple-Negative Breasat Cancer; Tumor Immune Microenvironment; Tumor-Associated Macrophage

$872,100

Cell Signaling Pathways in Triple Negative Breast Cancer: Effects on Stemness Cell, Cell Survival, and The Tumor Micorenvironment

SupervisorCIHR2022Canada Graduate Scholarships - Michael Smith Foreign Study Supplements

Principal investigators: Gray, Aidan

Keywords: Breast Cancer; Cell Survivial; Tumor

$6,000

The role of Hedgehog signaling in basal-like breast cancer and the tumour microenvironment

SupervisorCIHR2019Doctoral Research Award: Canada Graduate Scholarships

Principal investigators: Marini, Wanda

Keywords: Breast Cancer; Immunotherapy; Oncology; Translational Research; Tumor Microenvironment

$105,000

Priming Notch-activated basal like breast cancer for immune checkpoint blockade

Nominated PICIHR2017Project Grant

Principal investigators: Reedijk, Michael

Keywords: Breast Cancer; Cytokines; Immune Cells; Immunotherapy; Notch Signaling; Tumor Microenvironment

$918,000

Wide-field polarimetric imaging for targeted and rapid high-sensitivity analysis of breast cancer margins and heterogeneity with mass spectrometry

Co-investigatorCIHR2017Project Grant

Principal investigators: Vitkin, I. Alex; Zarrine-Afsar, Arash

Keywords: Breast Cancer Heterogeneity; Breast Cancer Surgery; Depolarization And Birefringence; Detection Sensitivity And Specificity; Gentle Localized Laser Ablation; Margin Characterization; Mass Spectrometry; Mass Spectrometry Point Sensing And Imaging; Mueller Matrix Polarimetry; Pathology Assessment

$795,600

Identification of molecular pathways associated with Notch activation in triple-negative breast cancer

Nominated PICIHR2009Operating Grant

Principal investigators: Reedijk, Michael

Keywords: Breast Cancer; Chromosomal Immunoprecipitation; Notch Signaling; Shrna Interference

$346,950

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Frequent collaborators

Surgery
Department of Surgery
Biostatistics Division
Health Research Methods, Evidence, and Impact
Medical Imaging
Pathology & Molecular Medicine
Oncology
Other

1 shared papers, latest 2009

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their CIHR grant from 2026

Subject: Prospective PhD student: Immunotherapy Dear Professor Reedijk, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "A handheld device for intra-cavity and ex vivo fluorescence imaging of breast conserving surgery margins with 5-aminolevulinic acid." (2024), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "Rebooting Sensitivity to Checkpoint Blockade Therapy in TNBC (RESETT)" (2026), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]

Michael Reedijk

Research

Latest papers

Latest funding

A handheld device for intra-cavity and ex vivo fluorescence imaging of breast conserving surgery margins with 5-aminolevulinic acid.

Inhibition of Notch enhances efficacy of immune checkpoint blockade in triple-negative breast cancer.

Evaluating persistent T1-weighted lesions without concurrent abnormal enhancement on breast MRI in neoadjuvant chemotherapy patients: implications for complete pathological response.

Caspase-1-dependent spatiality in triple-negative breast cancer and response to immunotherapy.

Exploring immune interactions in triple negative breast cancer: IL-1&#x3b2; inhibition and its therapeutic potential.

Targeting Notch-Driven Cytokine Secretion: Novel Therapies for Triple Negative Breast Cancer.

2023 Canadian Surgery Forum

Therapeutic inhibition of USP9x-mediated Notch signaling in triple-negative breast cancer.

Lack of definitive presurgical pathological diagnosis is associated with inadequate surgical margins in breast-conserving surgery.

Notch Signaling and the Breast Cancer Microenvironment.

Rebooting Sensitivity to Checkpoint Blockade Therapy in TNBC (RESETT)

Cell Signaling Pathways in Triple Negative Breast Cancer: Effects on Stemness Cell, Cell Survival, and The Tumor Micorenvironment

The role of Hedgehog signaling in basal-like breast cancer and the tumour microenvironment

Priming Notch-activated basal like breast cancer for immune checkpoint blockade

Wide-field polarimetric imaging for targeted and rapid high-sensitivity analysis of breast cancer margins and heterogeneity with mass spectrometry

Identification of molecular pathways associated with Notch activation in triple-negative breast cancer

Frequent collaborators

Alexandra Easson

Lisa Wang

Marcus Butler

Tulin Cil

Gabriela Gohla

Colm Boylan

Nicole Hodgson

Peter Lovrics

Charles Harry Goldsmith

Holger Hirte

Naoto Hirano

Kazuhiro Yasufuku

Anna Spreafico

Chiara Gorrini

Julie Hallet

Daniel McIsaac

Eitan Prisman

Melanie Tsang

Manoj Lalu

Gary Groot

Antoine Eskander

Monakshi Sawhney

Marco Magalhaes

Sunil Patel

Angela Jerath

John Kuruvilla

Kednapa Thavorn

Krista Hardy

Sebastien Hotte

Timothy Whelan

Edward Passos

John Agzarian

Paul Engels

Ilun Yang

Dennis Hong

Elaine McWhirter

Bobby Shayegan

Filgen Fung

Mark Norman Levine

Anita Bane

Exploring immune interactions in triple negative breast cancer: IL-1β inhibition and its therapeutic potential.